RNXT PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

RNXT ▲ +12.03% at T+20d

NEUTRAL call ✓ call won +12.03% · α vs SPY +6.57% · entry $0.8310 → $0.9310

Next anchor: T+60d in 6w

Last close $0.8440 (close Jun 12) · +1.56% from $0.8310 entry

Entry anchored
Apr 28, 03:37 PM ET
via Databento tick

T+1d

+2.29%

call +2.29% · α +1.26%

$0.8500

settled 7w ago

T+5d

+11.67%

call +11.67% · α +8.56%

$0.9280

settled 6w ago

T+20d

+12.03%

call +12.03% · α +6.57%

$0.9310

settled 18d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

RenovoRx announced its Q1 2026 earnings conference call for May 14, 2026, with no financial results in this press release. The company highlighted commercial progress with RenovoCath sales of ~$1.1M in its first full year and the Phase III TIGeR-PaC trial nearing full enrollment. The filing is a routine earnings date announcement with no new financial data, making it neutral for traders.

Actionable Insight

Wait for the May 14 earnings call for actual Q1 2026 financials and guidance. The ~$1.1M annual RenovoCath sales figure is a baseline to compare against; any acceleration or deceleration in Q1 sales will be the key catalyst.

Key Facts

Q1 2026 earnings call scheduled for May 14, 2026 at 4:30 pm ET
First full year of RenovoCath commercial sales generated approximately $1.1 million
Phase III TIGeR-PaC trial nearing full enrollment, on track for completion in H1 2026 with final data expected in 2027
No Q4 2025 financial results released in this press release; prior quarter EPS was $-0.08, in line with consensus

Financial Impact

No new financial data in this filing; prior quarter revenue was $463K and EPS was $-0.08

Risk Factors

No financial results in this filing; stock may trade on anticipation ahead of May 14 call
Micro-cap biotech with high cash burn risk; TIGeR-PaC trial results are binary event risk for 2027
Historical performance shows poor stock reaction to prior filings; neutral events have seen -13% average T+5 moves

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3283750

14 reports for RNXT

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +7.56%May 14, 2026

Filters

Reports for RNXT — sortable, filterable
	Type				Now
May 26, 2026 19d ago	Press Release BULLISH ★ 5/10	$0.9160 $0.9210	▲ +0.55%	▼ −0.54%	$0.8440 (−7.86%)
May 19, 2026 26d ago	Press Release NEUTRAL ★ 3/10	$0.8060 $0.9052	▲ +12.31%	▲ +10.06%	$0.8440 (+4.71%)
May 15, 2026 4w ago	10-K/A NEUTRAL ★ 4/10	$0.7830 $0.9160	▲ +16.99%	▲ +15.37%	$0.8440 (+7.79%)
May 14, 2026 4w ago	8-K BULLISH ★ 5/10	$0.8200 $0.8820	▲ +7.56%	▲ +6.60%	$0.8440 (+2.93%)
Apr 29, 2026 6w ago	Press Release NEUTRAL ★ 3/10	$0.8310 $0.9280	▲ +11.67%	▲ +8.56%	$0.8440 (+1.56%)
Apr 28, 2026 6w ago	EFFECT NEUTRAL ★ 4/10	$0.8400 $0.9280	▲ +10.48%	▲ +8.78%	$0.8440 (+0.48%)
Apr 16, 2026 8w ago	S-3 NEUTRAL ★ 4/10	$1.00 $0.8570	▼ −14.30%	▼ −14.85%	$0.8440 (−15.60%)
Apr 14, 2026 8w ago	Press Release BULLISH ★ 7/10	$1.03 $0.9490	▼ −7.86%	▼ −9.26%	$0.8440 (−18.06%)
Mar 30, 2026 10w ago	8-K MIXED ★ 6/10	$1.01 $0.9390	▼ −7.03%	▼ −10.97%	$0.8440 (−16.44%)
Mar 30, 2026 10w ago	Press Release MIXED ★ 6/10	$1.01 $0.9390	▼ −7.03%	▼ −10.97%	$0.8440 (−16.44%)

US Market Status

Market Closed — Opens in 4h 41m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access